Stanley Iyadurai

Stanley Iyadurai, M.D., Ph.D., currently serves as Senior Vice President, Medical Affairs and Drug Discovery since March 2023. Dr. Iyadurai joined Catalyst in August 2018 as Vice President of Clinical Development, bringing to Catalyst an extensive background in basic sciences and clinical research, and deep expertise with neurology and neuromuscular disorders. Prior to joining Catalyst, Dr. Iyadurai served as Global Clinical Program Director, Clinical Research and Development at CSL Behring, where he was responsible for managing/directing global neurology/immunology late-phase, POC, pre-clinical studies and evaluating companies/novel compounds for acquisition/drug discovery.

Previously, Dr. Iyadurai was a full-time faculty member at the Ohio State University Division of Neuromuscular Medicine, Departments of Neurology and Pediatric Neurology at Nationwide Children’s Hospital and at Saint Louis University in the Departments of Neurology, Pediatrics and Pathology, where he focused on neuromuscular disorders. Dr. Iyadurai also served as the Director of the Neuromuscular Genetics Clinic at the Ohio State University. As a licensed and practicing physician, Dr. Iyadurai holds a per diem Neuromuscular Specialist position at the Johns Hopkins All Children’s Hospital, St Petersburg, FL, where he co-directs the Muscular Dystrophy Association Clinic. Dr. Iyadurai has experience in basic science and clinical research, significant rare disease experience, and clinical trial experience as either the Principal Investigator or one of the sub-Investigators in more than 40 clinical trials and has published multiple research articles in peer-reviewed journals.

Dr. Iyadurai received M.D. and Ph.D. degrees from the University of Minnesota.